9468:TSEKadokawa Corporation Analysis
Data as of 2026-06-19 - not real-time
¥3,278.00
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Kadokawa’s share price sits well above its DCF-derived fair value, indicating a pronounced overvaluation. The trailing P/E of several hundred times far exceeds the industry average, while the forward P/E remains high despite a projected earnings surge. Revenue is growing at a double‑digit pace and the forward EPS outlook suggests a sharp earnings acceleration. However, operating margins are still negative and free cash flow is in the red, raising concerns about cash generation. The dividend payout ratio is well above 300%, which is unsustainable given the current cash flow profile.
Technical indicators show a neutral market stance, with the MACD turning mildly bullish and the RSI hovering around the midpoint. Volume has been rising, but the price remains trapped between a solid support level near 3,050 and resistance around 3,450. Volatility is elevated at over 35% and the beta is low, suggesting price swings are driven more by company‑specific factors than market moves. Sector exposure to publishing and digital media carries medium risk, while regulatory and geographic risks are relatively low. Overall, the stock appears overvalued with limited upside, making a defensive stance prudent. For investors seeking short‑term exposure, a hold is advisable pending clearer earnings momentum. Longer horizons are better served by a cautious sell recommendation until valuation aligns with fundamentals.
Technical indicators show a neutral market stance, with the MACD turning mildly bullish and the RSI hovering around the midpoint. Volume has been rising, but the price remains trapped between a solid support level near 3,050 and resistance around 3,450. Volatility is elevated at over 35% and the beta is low, suggesting price swings are driven more by company‑specific factors than market moves. Sector exposure to publishing and digital media carries medium risk, while regulatory and geographic risks are relatively low. Overall, the stock appears overvalued with limited upside, making a defensive stance prudent. For investors seeking short‑term exposure, a hold is advisable pending clearer earnings momentum. Longer horizons are better served by a cautious sell recommendation until valuation aligns with fundamentals.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- neutral technical momentum
- pronounced overvaluation
- increasing volume but limited upside
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- expected earnings acceleration
- still stretched valuation
- cash flow constraints
Long Term
> 3 yearsCautious
Model confidence: 7/10
Key Factors
- significant overvaluation vs DCF
- weak cash generation and high debt
- low ROE limiting returns
Key Metrics & Analysis
Financial Health
Revenue Growth12.00%
Profit Margin0.45%
P/E Ratio376.8
ROE1.47%
ROA0.83%
Debt/Equity3.95
P/B Ratio1.9
Op. Cash Flow¥3.4B
Free Cash Flow¥-11175374848
Industry P/E16.7
Technical Analysis
TrendNeutral
RSI49.3
Support¥3,054.00
Resistance¥3,453.00
MA 20¥3,252.80
MA 50¥3,400.26
MA 200¥3,324.26
MACDBullish
VolumeIncreasing
Fear & Greed Index91.46
Valuation
Fair Value¥1,077.65
Target Price¥3,194.29
Upside/Downside-2.55%
GradeOvervalued
TypeBlend
Dividend Yield1.93%
Risk Assessment
Beta0.25
Volatility35.23%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.